All In Biotech

NDA 212526 · Novartis

Piqray

Alpelisib · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

May 24, 2019

Approved uses

3

Original approval plus efficacy supplements

Registered trials

109

10 Phase 3, 22 recruiting

FAERS reports

8,387

4,816 serious, 1,229 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 28, 2026.

PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after an endocrine-based regimen. PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-authorized test following progression on or after an endocrine-based regimen. ( 1 , 2.1 )

Mechanism: Alpelisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3Kα. Gain-of-function mutations in the gene encoding the catalytic α-subunit of PI3K (PIK3CA) lead to activation of PI3Kα and Akt-signaling, cellular transformation and the generation of tumors in in vitro and in vivo models. In breast cancer cell lines, alpelisib inhibited the phosphorylation of PI3K downstream targets, including Akt and showed activity in cell lines harboring a PIK3CA mutation. In vivo, alpelisib inhibited the PI3K/Akt signaling pathway and reduced tumor growth...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 18, 2024 Supplement 9 · Efficacy · priority review LetterLabel
  • Nov 22, 2022 Supplement 7 · Efficacy LabelLetter
  • May 24, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
3 products under this application
  • PIQRAY · ALPELISIB 150MG · TABLET, ORAL · Prescription
  • PIQRAY · ALPELISIB 200MG · TABLET, ORAL · Prescription
  • PIQRAY · ALPELISIB 50MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Alpelisib" as an intervention, any sponsor and status, largest first.

All 109 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hyperglycaemia1,498
  • rash1,384
  • diarrhoea1,320
  • blood glucose increased1,120
  • death900
  • nausea847
  • fatigue839
  • decreased appetite541
  • malignant neoplasm progression519
  • weight decreased519
  • vomiting484
  • drug ineffective376

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20161
20176
20184
2019802
20201,738
20211,761
20221,704
20231,386
2024504
2025266
2026214

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Piqray (Alpelisib)

2024 spending

$110M

Beneficiaries

1,177

5,211 claims

Per beneficiary

$93,255

$475.57 per unit

View as table
YearSpending
2020$145,606,866
2021$124,059,404
2022$122,245,171
2023$138,440,781
2024$109,761,432

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 56 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.